SHR-2173

DRUG2 trials

Sponsors

Guangdong Hengrui Pharmaceutical Co., Ltd

Conditions

Healthy VolunteersSystemic Lupus Erythematosus

Phase 1

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus

CompletedNCT06955598

Guangdong Hengrui Pharmaceutical Co., LtdSystemic Lupus Erythematosus

Start: 2024-11-24End: 2025-11-21Updated: 2025-12-15

Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects

CompletedNCT06995001

Guangdong Hengrui Pharmaceutical Co., LtdHealthy Volunteers

Start: 2024-04-28End: 2024-11-28Updated: 2025-05-29